Amneal Pharmaceuticals LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$25.1M
Doctors Paid
17,050
Transactions
91,736
2024 Total
$3.1M
Payment Breakdown by Category
Research$16.5M (65.8%)
Food & Beverage$1.6M (6.5%)
Consulting$1.1M (4.3%)
Travel$354,283 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16.5M | 1,818 | 65.8% |
| Honoraria | $3.8M | 1,968 | 15.0% |
| Food and Beverage | $1.6M | 85,513 | 6.5% |
| Consulting Fee | $1.1M | 722 | 4.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $758,346 | 697 | 3.0% |
| Grant | $383,531 | 39 | 1.5% |
| Travel and Lodging | $354,283 | 761 | 1.4% |
| Education | $326,194 | 160 | 1.3% |
| Charitable Contribution | $254,000 | 58 | 1.0% |
Payments by Type
Research
$16.5M
1,818 transactions
General
$8.6M
89,918 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS | $3.2M | 0 | 327 |
| A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations | $3.0M | 1 | 539 |
| AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS | $1.5M | 0 | 437 |
| A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF CARBIDOPA IN HEALTHY SUBJECTS. | $1.5M | 1 | 20 |
| A Multiple Site Study to Compare the Cumulative Skin Irritation and Sensitization Potential of a Test Product Transdermal System Compared to the Marketed Estradiol Transdermal System (DS320116) | $1.2M | 0 | 27 |
| An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fluctuations | $990,630 | 0 | 259 |
| A Study to Evaluate the Cumulative Skin Irritation and Sensitization Potential of a Generic Norelgestromin and Ethinyl Estradiol Transdermal System 15035 mcg per day to that of Xulane Transdermal System in Normal Healthy Adult Human Female Subjects under Fasting Conditions | $955,800 | 0 | 1 |
| A Multi-Center Study to Evaluate the Skin Irritation and Sensitization Potential of a Vehicle Patch (for Buprenorphine Transdermal System) (Amneal Pharmaceuticals) (11749706) | $519,100 | 0 | 3 |
| Open-Label, Single-Application, Two-Treatment, Two-Period, Crossover Pivotal Adhesion Study of One Test Formulation of Estradiol Film, Extended Release Transdermal 0.1 mg/24 hour (Amneal Pharmaceuticals) Compared to Minivelle (estradiol transdermal system) 0.1 mg/24 hour (Noven Pharmaceuticals,Inc.) in Healthy Post-Menopausal Female Subjects (38115) | $413,810 | 0 | 2 |
| Supratherapeutic Dose of Carbidopa in Healthy Subjects | $359,897 | 1 | 1 |
| BIMATOPROST | $358,475 | 2 | 46 |
| A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Carbidopa in Healthy Subjects | $327,996 | 1 | 5 |
| Randomized, Open-Label, 2-way Crossover Bioequivalence Study of Doxepin Cream, 5 Manufactured by Amneal Pharmaceuticals LLC and Zonalon Doxepin Cream, 5 Marked by Bioglan Phamra Inc. Following a 3-Gram Dose to Healthy Subjects 172005 | $299,133 | 0 | 6 |
| Randomized, Open-Label, 2-way Crossover Bioequivalence Study of Dapsone Gel, 5% Manufactured by Amneal Pharmaceuticals and ACZONE (dapsone) Gel, 5% Marked by Allergan, Inc. Following a 3-Gram Dose to Healthy Subjects (172005) | $245,083 | 0 | 3 |
| Single Dose Crossover Comparative Bioavailability Study of Morphine Sulfate ER Capsules USP 100mg Tablets in Healthy Adult Subjects under Fasting State | $220,023 | 0 | 1 |
| Single Dose Crossover Comparative Bioavailability Study of Oxycodone 40mg Extended-Release Tablets in Healthy Male and Female Volunteers/Fasting State (ANL-P0-462) | $177,863 | 0 | 3 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZOLMITRIPTAN NASAL SPRAY FOR THE TREATMENT OF ACUTE MIGRAINE IN SUBJECTS AGES 6 TO 11 YEARS, WITH AN OPEN-LABEL EXTENSION | $176,907 | 0 | 49 |
| Single Dose Parallel Study to Determine the Residual Contnt of Ethinyl Estradiol/etonogestrel 11.7 mg/2.7 mg Vaginal Ring Delivering 0.015 mg/0.120 mg Per Day Following a Wear Period of 21 Days in Healthy Female Volunteers (ANL-P9-348) | $166,668 | 0 | 2 |
| A Multiple Site Study to Compare the Cumulative Skin Irritation and Sensitization Potential of a Test Product Transdermal System Compared to the Marketed Estradiol Transdermal System DS320116 | $152,669 | 0 | 13 |
| A Study to Evaluate the Relative Bioavailability of a Test Formulation of Amphetamine Sulfate Tablets USP, 10mg [CII] (Amneal Pharmaceuticals) Compared to EVEKEO (amphetamine sulfate tablets, USP) CII, 10mg (Arbor Pharmaceuticals, LLC) in Healthy Adult Subjects under Fasted Conditions (11649726) | $140,998 | 0 | 5 |
| A Multi Center Study to Evaluate the Skin Irritation and Sensitization Potential of a Vehicle Patch for Buprenorphine Transdermal System Amneal Pharmaceuticals 11749706 | $138,975 | 0 | 2 |
| A Study to Evaluate the Skin Irritaiton of a Test Norelgestromin and Ethinyl Estradiol Transdermal System 15035 mcg per day Amneal Pharmaceuticals LLC to Xulane norelgestromin and ethinyl estradiol transdermal system 15035 mcg per day Mylan Pharmaceuticals Inc. - 11849703 | $115,000 | 0 | 4 |
| REMS-RADARS | $83,199 | 0 | 1 |
| A Study to Evaluate the Relative Bioavailability of a Test Formulation of Amphetamine Sulfate Tablets USP, 10mg [CII] (Amneal Pharmaceuticals) Compared to EVEKEO (amphetamine sulfate tablets, USP) CII, 10mg (Arbor Pharmaceuticals, LLC) in Healthy Adult Subjects under Fed Conditions (11649727) | $75,922 | 0 | 3 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy And Safety Of Zolmitriptan Nasal Spray For The Treatment Of Acute Migraine In Subjects Ages 6 To 11 Years, With An Open-Label Extension | $51,632 | 0 | 32 |
| Open-Label, Single-Application, Two-Treatment, Two-Period, Crossover Pivotal Adhesion Study of One Test Formulation of Estradiol Film, Extended Release Transdermal 0.1 mg24 hour Amneal Pharmaceuticals Compared to Minivelle estradiol transdermal system 0.1 mg 24 hour Noven Pharmaceuticals,Inc in Healthy Post-Menopausal Female Subjects 38115 | $48,075 | 0 | 1 |
| A Study to Evaluate the Relative Bioavailability of a Test Formulation of Dapsone Gel, 5% (Amneal Pharmaceuticals) Compared to ACZONE (dapsone) Gel, 5% (Allergan, Inc.) in Healthy Adult Male Subjects (11649701) | $41,910 | 0 | 1 |
| A Single-Dose Randomized Open-Label, Pilot Comparative Bioavailability Study of Trentine 250 mg Capsules (Amneal Pharmaceuticals) and SYPRINE (trientine hydrochloride) 250mg Capsules (Valeant Pharmaceuticals North America, USA) in Health Male and Female Volunteers under Fasting Conditions (2023) | $12,982 | 0 | 1 |
| Antiretroviral Pregnancy Registry (APR) | $1,320 | 1 | 23 |
| Pilot, Randomized, Open-Label, 2-way Crossover Comparative Bioequivalence Study of Dapsone Gel, 5% and ACZONE (dapsone) Gel, 5% (Reference) Following a 3 Grams Dose to Healthy Subjects (162005) | $694.47 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| John Mickelson, Do, DO | Family Medicine | Lincoln City, OR | $859,157 | $0 |
| Robert Hauser, Md, MD | Neurology | Tampa, FL | $390,364 | $0 |
| Ramsey Falconer, M.d, M.D | Neurology | Alexandria, VA | $368,993 | $0 |
| Dr. Cherian Karunapuzha, Md, MD | Neurology | Oklahoma City, OK | $354,731 | $0 |
| Maria Ospina, Md, MD | Neurology | Phoenix, AZ | $328,114 | $0 |
| Dr. Laxman Bahroo, D.o,, D.O, | Neurology | Washington, DC | $286,351 | $0 |
| Dr. Stuart Isaacson, Md, MD | Neurology | Boca Raton, FL | $254,571 | $0 |
| John Morgan, Md, MD | Neurology | Augusta, GA | $254,542 | $0 |
| Dr. Salima Brillman, Md, MD | Psychiatry | Sunnyvale, CA | $227,885 | $0 |
| Dr. Richard Trosch, M.d, M.D | Neurology | Farmington Hills, MI | $219,612 | $0 |
| Dr. Yasar Torres-Yaghi, M.d, M.D | Neurology | Washington, DC | $212,031 | $0 |
| Dr. David Kreitzman, M.d, M.D | Neurology | Commack, NY | $182,697 | $0 |
| Khashayar Dashtipour, M.d, M.D | Neurology | Loma Linda, CA | $180,006 | $0 |
| Mr. David Wirta, Md, MD | Ophthalmology | Newport Beach, CA | $172,650 | $0 |
| Aanchal Taneja, Md, MD | Neurology | Dallas, TX | $108,269 | $0 |
| Ramon Gil, Md, MD | Specialist | Port Charlotte, FL | $106,159 | $0 |
| Dr. Rajeev Kumar, Md, MD | Neurology | Englewood, CO | $100,438 | $0 |
| William Ondo, M.d, M.D | Neurology | Houston, TX | $91,358 | $0 |
| Fernando Pagan | Neurology | Washington, DC | $89,249 | $0 |
| Dr. Daniel Kremens, M.d., J.d, M.D., J.D | Neurology | Philadelphia, PA | $87,603 | $0 |
| Pinky Agarwal, Md, MD | Specialist | Kirkland, WA | $86,857 | $0 |
| Dr. Michael Soileau, Md, MD | Neurology | Georgetown, TX | $80,057 | $0 |
| Dr. Sandeep Thakkar, D.o, D.O | Neurology | Irvine, CA | $72,100 | $0 |
| Dr. Juan Ramirez Castaneda, M.d, M.D | Neurology | San Antonio, TX | $71,119 | $0 |
| Dr. Fiona Gupta, M.d, M.D | Neurology | Oradell, NJ | $71,043 | $0 |
Ad
Top Products
- RYTARY $5.3M
- IR CD-LD $4.1M
Associated Products (25)
- RYTARY $5.9M
- IR CD-LD $4.1M
- Estradiol TDS $1.7M
- CARBIDOPA AND LEVODOPA $1.6M
- CREXONT $1.2M
- NORELGESTROMIN $1.1M
- IPX203 $865,538
- Rytary $730,192
- UNITHROID $583,188
- Buprenorphine TDS $519,100
- DOXEPIN $280,614
- Dapsone Gel $245,777
- MORPHINE SULFATE ER CAPSULES USP $220,023
- Buprenorphine HCl Naloxone HCl DiHydrate Sublinqual Tablets 2 mg/0.5mg $190,777
- Amphetamine 10mg $184,382
- Oxycodone ADF $177,863
- Ethinyl Estradiol/Etonogestrel Vaginal Ring $166,668
- LYVISPAH $68,941
- ONGENTYS 50MG CAPSULES 30 $66,367
- Dapsone Gel 5% $41,910
- Fluocinonide Cream 0.05% $32,538
- Tigecycline (73 H) $25,550
- AVASTIN $25,292
- OXYCODONE $18,519
- Treintine HCl $12,982
Payment Categories
- Food & Beverage $1.6M
- Consulting $1.1M
- Travel & Lodging $354,283
- Research $16.5M
About Amneal Pharmaceuticals LLC
Amneal Pharmaceuticals LLC has made $25.1M in payments to 17,050 healthcare providers, recorded across 91,736 transactions in the CMS Open Payments database. In 2024, the company paid $3.1M. The top product by payment volume is RYTARY ($5.3M).
Payments were distributed across 183 medical specialties. The top specialty by payment amount is Neurology ($5.8M to 3,383 doctors).
Payment categories include: Food & Beverage ($1.6M), Consulting ($1.1M), Research ($16.5M), Travel & Lodging ($354,283).
Amneal Pharmaceuticals LLC is associated with 25 products in the CMS Open Payments database, including RYTARY, IR CD-LD, and Estradiol TDS.